Imprimis Pharmaceuticals Licenses IP

San Diego-based Imprimis Pharmaceuticals said this morning that it has licensed a set of intellectual property assets, from Buderer Drug Company. Financial details of the licensing deal were not announced. Imprimis said it is developing innovations based on technology from the compounding pharmacy operations of Buderer. Imprimis said it is in the process of filing for a patent on those new IP assets. The company did not say what segment of the market the new assets would target.